ArticleBMC cancer2026
Long-term risk of depression in lung, colon, breast, and prostate cancer: a 25-year nationwide comparative study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression is common among patients with cancer, but its occurrence may vary across cancer types with differing prognoses and symptom burdens. This nationwide study examined the long-term development of depression among patients with lung, colon, breast, and prostate cancer.
methodsUsing Danish health registries (1998–2022), we identified all individuals with a first diagnosis of lung, colon, breast, or prostate cancer. Depression was assessed through hospital-based diagnoses or antidepressant prescriptions (≥ 2 dispensations within two years after diagnosis). Logistic regression models estimated odds ratios (ORs) for antidepressant initiation among cancer types, adjusted for age, marital status, municipality, educational attainment, and comorbidity (Quan adaptation of the Charlson Comorbidity Index).
resultsThe study included more than 280,000 patients with cancer. Antidepressant use before diagnosis was more frequent among lung cancer compared with colon, breast, and prostate cancer. Following diagnosis, 1-year antidepressant use reached 16.8% in men and 24.9% in women with lung cancer, approximately twice the corresponding rates in other cancers. Adjusted analyses confirmed, that patients with lung cancer were more likely to initiate antidepressant therapy than those with colon, breast, or prostate cancer (adjusted ORs 1.9–2.5, p < 0.001). Depression diagnoses showed a similar, though less pronounced, pattern.
conclusionsPatients with lung cancer exhibit a substantially higher long-term risk of depression – even after adjustment compared to colon, breast, and prostate cancer - both before and after cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.